Company / Cash & Equivalents
Core Scientific, Inc./tx Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$311.4M
FY2025
5-year range
$15.9M / $836.2M
FY2021-FY2025
Trend
-62.8%
vs FY2024
Sector context
#165 of 258
Financials
What the data says
At $311M, Core Scientific, Inc./tx's cash & equivalents ranks #165 of 258 in the Financials sector. Improved from $50M to $311M over the past 2 years.
Based on SEC 10-K filings.
$311M in FY2025 with a 3-year CAGR of +169.6%.
Improved from $50M to $311M over the past 2 years.
Financials sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +169.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#165 of 258 in FinancialsTop 64% of 258This company $311.4M Sector average $2.8B
▼
-88.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +169.6%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 62.8% year-over-year.
- Ranks #165 out of 258 companies in the Financials sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $311.4M | -62.8% |
| FY2024 | $836.2M | +1558.8% |
| FY2023 | $50.4M | +217.4% |
| FY2022 | $15.9M | -86.5% |
| FY2021 | $117.9M | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026